Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):251-256. doi: 10.1097/ACI.0000000000000999. Epub 2024 May 30.
To acknowledge, the newly available treatments for food allergy described in the latest scientific literature, such as oral immunotherapy (OIT), biologics and the combination of them in managing patients with IgE-mediated food allergies.
Recent studies suggest that OIT and biologics, alone or together, can have a role as disease-modifying treatments for food allergies. The FDA has recently approved omalizumab as a treatment for food allergy. Other biologics are currently under evaluation and further studies are needed to assess the efficacy and safety of these therapies.
The allergology scenario is rapidly evolving, the recent introduction and approval of new therapeutic strategies such as biotechnological drugs and allergen immunotherapy is changing the therapeutic paradigm: we are witnessing a shift from a strategy based on avoiding the trigger and reversing an allergic reaction already in progress, to one that aims to modify the natural history of the disease by acting on the immunological mechanisms that determine it. This approach is consistent with the modern perspective of a personalized patient-tailored medicine. In this opinion review, we will provide a brief analysis of current and future therapeutic options for IgE-mediated food allergy, focusing on OIT, biologics and their combination.
在最新的科学文献中，承认新的食物过敏治疗方法，如口服免疫疗法（OIT）、生物制剂以及它们联合用于管理 IgE 介导的食物过敏患者。
最近的研究表明，OIT 和生物制剂单独或联合使用可以作为食物过敏的疾病修饰治疗。FDA 最近批准奥马珠单抗用于治疗食物过敏。其他生物制剂目前正在评估中，需要进一步研究来评估这些疗法的疗效和安全性。
过敏学领域正在迅速发展，最近引入和批准新的治疗策略，如生物技术药物和过敏原免疫疗法，正在改变治疗模式：我们正在见证从基于避免触发因素和逆转已经发生的过敏反应的策略向通过作用于决定疾病的免疫机制来改变疾病自然史的策略转变。这种方法符合个性化患者定制医学的现代观点。在本观点综述中，我们将简要分析 IgE 介导的食物过敏的当前和未来治疗选择，重点关注 OIT、生物制剂及其联合应用。
